Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...

BlackRock 80/20 Target Allocation Fund earns an Above Average Process Pillar rating. The predominant contributor to the rating is the fund's impressive long-term risk-adjusted performance.

CAE Inc (NYSE:CAE). reported its fourth-quarter 2024 earnings, surpassing both earnings per share (EPS) and revenue forecasts. The company's EPS came in at $0.29, slightly above the forecasted $0.28.